Vanda Pharmaceuticals (VNDA) Invested Capital (2024 - 2025)

Vanda Pharmaceuticals (VNDA) reported Invested Capital of $7.5 million for Q4 2025, up 50.79% on a YoY basis from $5.0 million in Q4 2024, and up 50.79% sequentially from $5.0 million in Q4 2024.

Vanda Pharmaceuticals (VNDA) Invested Capital (2024 - 2025) Analysis & Trends

Vanda Pharmaceuticals (VNDA) has 2 years of Invested Capital data on file, last reported at $7.5 million in Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital rose 50.79% year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (up 50.79% YoY), and the FY2025 full-year result was $7.5 million, up 50.79% from the prior year.
  • Invested Capital improved to $7.5 million in Q4 2025, from $5.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $7.5 million in Q4 2025 to a low of $5.0 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn - -
2 Nanobiotix 1,913.50 Bn 1,913.44 Bn - 110.96 Mn
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 473.74 Bn 468.95 Bn 1.35 Bn 116.14 Mn
5 Vertex Pharmaceuticals 122.07 Bn 114.82 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 70.00 Bn 61.24 Bn 3.31 Bn -
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.96 Bn 50.77 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn -
10 Vanda Pharmaceuticals 314.84 Mn 112.53 Mn 48.56 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 7.48 Mn
Dec 31, 2024 4.96 Mn